Loading organizations...
Longwood Fund operates as a venture capital firm dedicated to both creating and investing in innovative healthcare companies. The firm’s core mission involves identifying groundbreaking scientific discoveries and transforming them into viable companies that develop novel treatments for significant medical challenges. This is achieved by leveraging their deep operating experience and hands-on company-building approach, partnering with world-class entrepreneurs, scientists, and academic innovators.
The firm was co-founded by Christoph Westphal and Rich Aldrich, whose extensive pedigree in biotech company creation underpins Longwood's distinctive strategy. Their collective experience, which includes co-founding numerous biotechnology ventures prior to establishing the fund, provided the insight that a more integrated model of company building and investment was needed to translate scientific advancements into patient-benefiting therapies effectively.
Longwood Fund's ultimate beneficiaries are patients, who receive access to new and important treatments developed by the companies within its portfolio. The firm's vision is centered on making a meaningful difference in the lives of patients by accelerating the development of science-based innovations, while simultaneously generating substantial value for its investors through these impactful healthcare solutions.
Key people at Longwood Fund.
Longwood Fund has more than 26 tracked investments across 22 companies. The latest tracked deal is $76.0M Series B in Mediar Therapeutics in January 2026.
Key people at Longwood Fund.
Longwood Fund is a Boston-based venture capital firm specializing in healthcare investments, particularly in biotechnology, pharmaceuticals, and medical devices. Its mission centers on creating and investing in science-driven companies that develop novel therapies addressing significant unmet medical needs. The firm partners closely with world-class scientific founders to translate groundbreaking discoveries into impactful medical solutions, supporting companies from early-stage research through to patient delivery. Longwood Fund’s portfolio includes companies advancing therapies in oncology, mental health, genetic diseases, gene therapy, and chronic inflammatory diseases, reflecting a broad commitment to transformative healthcare innovation[1][2][4].
Founded in 2010, Longwood Fund was established with a focus on biotech and healthcare innovation. Key partners include Dr. Christoph Westphal, a co-founder and general partner, who has been instrumental in shaping the firm’s strategy and network within the Boston biotech ecosystem. Over time, Longwood Fund has evolved to not only invest capital but also take active roles in company formation and leadership, often partnering as co-founders or executive team members to accelerate development. This hands-on approach has helped the firm build a strong reputation for launching and scaling science-based healthcare companies[3][4].
Longwood Fund rides the wave of rapid advances in biotechnology and precision medicine, capitalizing on breakthroughs in gene editing, AI-driven drug discovery, and regenerative medicine. The timing is critical as healthcare increasingly shifts toward personalized, disease-modifying therapies that address previously untreatable conditions. Market forces such as rising healthcare demands, scientific innovation, and supportive regulatory environments favor Longwood’s focus. By fostering early-stage companies with strong scientific foundations, Longwood influences the broader ecosystem by accelerating the translation of cutting-edge research into real-world medical solutions[2][4].
Looking ahead, Longwood Fund is poised to continue expanding its footprint in transformative healthcare sectors, especially where novel modalities like gene therapy and AI-enabled drug development intersect. Trends such as precision oncology, neurotherapeutics, and chronic disease management will likely shape its investment focus. As the firm deepens its operational involvement and leverages its network, its influence on the biotech startup ecosystem is expected to grow, potentially setting new standards for venture capital engagement in science-driven healthcare innovation. This trajectory aligns with Longwood’s founding mission to improve patient outcomes through pioneering medical science[2][3][4].
